`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPR2016-01101
`
`Patent No. RE 38,551
`
`PATENT OWNER’S UPDATED MANDATORY NOTICES
`
`UNDER 37 C.F.R. § 42.8
`
`
`
`Patent No. RE 38,551
`
`Case No. lPR20l6—01 101
`
`Pursuant
`
`to 37 C.F.R.
`
`§ 42.8, Patent Owner Research Corporation
`
`Technologies, Inc. submits the following Updated Mandatory Notices to provide
`
`an update regarding related matters involving RE 38,551. All other information
`
`remains unchanged.
`
`A.
`
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`
`The related judicial proceedings involving RE 38,551 are shown below. On
`
`August 12, 2016, an Order issued in 1:13-cv-01206-LPS (consolidated) (Ex. 2004),
`
`intending to enter final judgment
`
`for the plaintiffs/patent owner against
`
`the
`
`defendants consistent with the Memorandum Opinion unsealed on August 15, 2016
`
`(Ex. 2003). See, e.g., EX. 2003 at 86—9l.
`
`
`
`A SeDiSp0siti0n.;.:tm*7 I
`I
`(Case Captionet“
`UCB, Inc. et al. v. Teva Pharmaceuticals USA Inc. Closed
`
`
`
`pending
`
`
`
`et al., 1:13-cv-01148—LPS (D. Del.)
`UCB, Inc. et al. v. Accord Healthcare Inc. et al.,
`
`1:13-cv-01206-LPS (D. Del.)
`
`UCB, Inc. et al. v. Alembic Pharmaceuticals Ltd,
`l:l3—cv—0l207-LPS (D. Del.)
`UCB, Inc. et al. v. Amneal P/*1armaceutical.s', LLC
`
`et al., 1:13-cv-01208-LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:13-cv-
`01209-LPS (D. Del.)
`
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`1:13-cv-0l2l0—LPS (D. Del.)
`
`UCB, Inc. et al. v. Breckenridge Pharmaceutical
`Inc. et al., 1:13-cv-0l21l—LPS (D. Del.)
`UCB, Inc. et al. v. Glenmark Generics Inc. USA et
`
`-l
`
`pending, consolidated with
`1:13-cv-01206-LPS (D. Del.)
`pending, consolidated with
`1:13-cv-01206-LPS (D. Del.)
`pending, consolidated with
`1:13-cv-01206-LPS (D. Del.)_4
`pending, consolidated with
`1:13-cv-01206-LPS (D. Del.)
`pending, consolidated with
`1:13-cv-01206-LPS (D. Del.)
`closed
`
`al., l:13—cv-01212-LPS (D. Del.)
`
`UCB, Inc. etal. v. Hetero USA Inc. etal, l:13—cv— closed
`01213-LPS (D. Del.)
`
`
`
`Patent No. RE 38,551
`
`Case No. lPR20l6—Ol 101
`
`
`
`,
`,
`I
`,
`at
`V
`Case Caption 7
`UCB, Inc. et al. v. Mylan Pharmaceuticals Inc. et
`al., 1:13-CV-01214-LPS (D. Del.)
`UCB, Inc. et al. V. Ranbaxy Laboratories Ltd. et
`al., l:13-CV-01215-LPS (D. Del.)
`UCB, Inc. et al. v. Sandoz Inca, l:13-cV—01216-
`LPS (D. Del.)
`
`.
`Disposition I
`pending, consolidated with
`1:13-cV—O1206-LPS (D. Del.)
`closed
`
`closed
`
`UCB, Inc. et al. v ScieGen Pharmaceuticals Inc. et Closed
`
`al., 1:13—cV-0l217—LPS (D. Del.)
`UCB, Inc. et al. V Sun Pharma Global FZE et al.,
`l:l3-CV-01218-LPS (D. Del.)
`UCB, Inc. et al. V. Watson Laboratories Inc. -
`
`Florida et al., 1:13-cV—Ol2l9—LPS (D. Del.)
`UCB, Inc. et al. V. Zydus Pharmaceuticals (USA)
`Inc. et al., l:l3-CV-01220-LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:14-CV-
`00834-LPS (D. Del.)
`
`UCB, Inc. et al. v. Sun Pharma Global FZE et al.,
`l_lIl3-CV-055l4 (N.D. Ill.)
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USA),
`Inc. et al., 3:l3—CV-04021 (D.N.J.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`1:l6—cV—0045l (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., 1:16—cV-
`00452 (D. Del.)
`
`pending, consolidated with
`1:13—cV—012O6—LPS (D. Del.)
`pending, consolidated with
`1:13—cV—01206—LPS (D. Del.)
`pending, consolidated with
`1:13-cV—0l206—LPS (D. Del.)
`pending, consolidated with
`1:13—cv—01206—LPS (D. Del.)
`closed
`
`l
`
`Closed
`
`pending
`
`pending
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR2016-01101
`
`Date: August 19, 2016
`
`Respectfully submitted,
`
` *ndrea G. Reister
`
`Registration No. 36,253
`Jennifer L. Robbins
`
`Registration No. 61,163
`COVINGTON & BURLING LLP
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 19th day of August
`
`2016,
`
`the foregoing Patent Owner’s Updated Mandatory Notices Under 37
`
`C.F.R. § 42.8 was served by electronic mail, by agreement of the parties, on the
`
`following counsel of record for Petitioner.
`
`Steven W. Parmelee (sparme1ee@wsgr.com)
`Michael T. Rosato (mrosato@wsgr.com)
`J ad A. Mills (jmills@wsgr.corn)
`Wilson Sonsini Goodrich & Rosati
`
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`
`Date: August 19, 2016
`
` //4
`
`Jennifer L. Robbins, Esq.
`Registration No.: 61,163